Woodcock Highlights US FDA Opioid Plans Amid Sen. Manchin And Others’ Criticisms
Executive Summary
The statement outlining opioid priorities in the FDA’s FY 2022 budget request comes on the heels of Sen. Manchin’s criticism of the acting commissioner and FDA opioid policy.
You may also be interested in...
US FDA’s Inspection Volume Projected To Return To Normal Levels In FY 2022 As Backlog Looms
Additional hiring in FDA’s FY 2022 budget request also is expected to help address the inspections delayed by the coronavirus pandemic.
Campaign Against Woodcock’s US FDA Commissioner Bid Has Begun
Opioid issues delayed Robert Califf’s confirmation as FDA commissioner. Could they prevent the nomination of Janet Woodcock?
Opioid Blister Pack Mandate Could Be Phased-In Based On Prescription Volume
US FDA seeks public input on potential advantages and challenges of requiring 5-, 10, and -15-count blister packs for certain opioids and the idea of staggering implementation.